Shanghai Fosun Pharmaceutical (Group) Co., Ltd. (stock code: 02196) released its Monthly Return for Equity Issuer for the period ended 28 February 2026. The total authorised share capital remained at RMB2.67 billion, with no increase or decrease recorded during the month. The issuer’s authorised H shares totaled 551.94 million, and its authorised A shares totaled 2.12 billion.

As of the end of February 2026, the issued H shares (excluding treasury shares) stood at 540.97 million, with 10.97 million treasury shares. The issued A shares (excluding treasury shares) were 2.10 billion, plus 19.91 million treasury shares. No changes in the number of issued shares (excluding treasury shares) or movement in treasury shares took place during this reporting period. The issuer confirmed that the public float of its H shares continues to meet the 5% threshold set for PRC issuers with other listed shares.

Regarding share-based incentives, the 2025 A Share Option Scheme had 4.45 million outstanding share options at the start of the month, with no new issuance or transfers to treasury shares. The 2025 H Share RSU Scheme carried 10.38 million granted but unvested restricted share units (RSUs) at month-end, also without changes. No new shares or treasury share transfers occurred under these schemes during the reporting period.